One event can prevent another outcome from being observed. A cancer study needs to explain how it handles such events when estimating the chance of an outcome.
For a recurrence outcome, death before recurrence may be a competing event; another endpoint may count death as part of a composite instead. Methodological work using relapse and non-relapse mortality illustrates why a cause-specific event rate and cumulative event probability answer different questions. Treating competing events as ordinary censoring can distort the estimated probability. Interpretation depends on the endpoint definition and analysis, rather than the name of the survival curve alone.
Shares Estimands and intercurrent events (ICH E9(R1)), Evidence from measurement to patient benefit.
Shares Estimands and intercurrent events (ICH E9(R1)), Kaplan-Meier curve, censoring and proportional hazards.
Shares Estimands and intercurrent events (ICH E9(R1)), Kaplan-Meier curve, censoring and proportional hazards.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/